HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Swami Padmanabhan Selected Research

ofatumumab

4/2010Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Swami Padmanabhan Research Topics

Disease

1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
04/2010
1Lymphadenopathy
04/2010
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
08/2008
1Neoplasms (Cancer)
08/2008
1Leukemia
06/2008
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2008

Drug/Important Bio-Agent (IBA)

1Alemtuzumab (Campath)FDA Link
04/2010
1fludarabineIBA
04/2010
1ofatumumabFDA Link
04/2010
1HLA-DRB1 Chains (HLA DRB1)IBA
08/2008
1HLA Antigens (Human Leukocyte Antigens)IBA
08/2008
1Cyclosporine (Ciclosporin)FDA LinkGeneric
08/2008
1Imatinib Mesylate (Gleevec)FDA Link
06/2008
1Dasatinib (BMS 354825)FDA Link
06/2008
1nilotinibFDA Link
06/2008

Therapy/Procedure

1Immunotherapy
04/2010
1Hematopoietic Stem Cell Transplantation
08/2008
1Therapeutics
06/2008